Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis.
Hsiangkuo YuanAniket NatekarJade ParkClinton G LauritsenEugene R ViscusiMichael J MarmuraPublished in: Regional anesthesia and pain medicine (2023)
In this descriptive study, intranasal ketamine served as an acute treatment for refractory chronic migraine by reducing headache intensity and improving quality of life with relatively tolerable adverse events. Most patients found intranasal ketamine effective and continued to use it despite these adverse events. Given the potential for overuse, it should be reserved for those clearly in need of more effective rescue treatment with appropriate safety precautions. Well-designed prospective placebo-controlled trials are necessary to demonstrate the efficacy and safety of intranasal ketamine in patients with migraine.
Keyphrases
- pain management
- end stage renal disease
- ejection fraction
- prognostic factors
- newly diagnosed
- randomized controlled trial
- intensive care unit
- chronic kidney disease
- liver failure
- study protocol
- drug induced
- peritoneal dialysis
- climate change
- double blind
- clinical trial
- combination therapy
- open label
- acute respiratory distress syndrome